Revive Therapeutics provides information update on Bucillamine and Mpox

Revive Therapeutics announced an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre DRDC an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. The research study is progressing and is expected to be now completed in October 2024.The results from this research study, if promising, will determine further studies to facilitate FDA and Health Canada approvals for the use of Bucillamine in nerve agents or organophosphate pesticide poisoning, and explore its potential in viral infections, including monkeypox Mpox. In 2023, the World Health Organization released a Mpox fact sheet suggesting that severe cases of Mpox result in a number of conditions including inflammation of the brain, heart, rectum, genital organs and urinary passages…The Company would like to make it clear that it is not making any express or implied claims that its product Bucillamine has the ability to treat, eliminate or cure Monkeypox Mpox and/or other infectious diseases at this time